Clinical Characteristics and Immunophenotypic Analysis of RA Patients
| Patients . | Group . | Sex . | Age (yrs) . | ARA Class . | RF . | Duration (yrs) . | Therapy . | Lymphocytes (×103) . | CD3+ (%) . | CD4+ (%) . | CD8+ (%) . | CD57+ (%) . | CD3+CD57+ (%) . | CD8+CD57+ (%) . | CD4+CD57+ . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | % . | μL . |
| MAAP | 1 | F | 61 | I | − | 20 | DPA, NSAID, S | 1.4 | 48.5 | 31.2 | 22.7 | 27.4 | 2.9 | 8.7 | 0.3 | 4.2 |
| ROBR | F | 41 | I | + | 12 | CSA, MTX, S | 1.4 | 83.0 | 65.5 | 18.5 | 9.1 | 6.7 | 5.3 | 0.5 | 7.0 | |
| GRMU | F | 31 | II | + | 11 | HCQ, NSAID, S, SSZ | 2.3 | 71.1 | 31.1 | 41.0 | 18.8 | 13.0 | 11.6 | 0.6 | 13.8 | |
| ROGR | F | 48 | II | + | 7 | CSA, MTX, S, NSAID | 2.8 | 74.5 | 53.9 | 22.8 | 11.1 | 5.3 | 6.3 | 0.6 | 16.8 | |
| TEAG | F | 64 | II | − | 14 | HCQ, NSAID, S | 1.6 | 67.5 | 46.8 | 21.2 | 18.8 | 11.9 | 7.7 | 0.7 | 11.2 | |
| OSGA | M | 40 | III | − | 11 | CSA, GST, MTX, NSAID, S | 2.2 | 88.1 | 55.4 | 33.6 | 7.5 | 2.6 | 3.0 | 0.7 | 15.4 | |
| GAAR | F | 63 | III | + | 5 | GST, MTX, NSAID, S | 1.4 | 87.7 | 70.7 | 19.8 | 3.1 | 1.4 | 1.4 | 0.7 | 9.8 | |
| BRCA | M | 39 | III | + | 1 | HCQ, MTX, NSAID, S, SSZ | 1.4 | 72.3 | 45.7 | 36.3 | 8.9 | 7.3 | 7.9 | 1.0 | 14.0 | |
| DAFR | M | 59 | II | − | 13 | GST, NSAID, S | 2.7 | 68.0 | 60.2 | 8.4 | 7.6 | 4.3 | 5.2 | 2.1 | 56.7 | |
| ANAP | M | 48 | II | + | 12 | AF, NSAID | 2.4 | 55.8 | 41.0 | 27.4 | 30.8 | 12.4 | 16.2 | 2.2 | 52.8 | |
| GESA | F | 71 | IV | + | 16 | NSAID, S | 1.4 | 49.7 | 29.8 | 51.3 | 45.1 | 18.2 | 31.1 | 2.2 | 30.8 | |
| CABO | F | 53 | II | − | 21 | NSAID, S | 1.6 | 48.0 | 32.5 | 37.4 | 38.5 | 9.5 | 20.1 | 2.5 | 40.0 | |
| ROPE | F | 56 | III | − | 15 | NSAID, S | 1.1 | 82.5 | 53.1 | 26.8 | 14.0 | 10.2 | 8.6 | 3.0 | 33.0 | |
| PIZI | M | 56 | II | + | 12 | HCQ, MTX, NSAID, S, SSZ | 0.6 | 78.0 | 54.0 | 23.7 | 22.4 | 18.4 | 12.9 | 3.3 | 19.8 | |
| CAZI | F | 52 | III | + | 12 | MTX, NSAID, S, SSZ | 1.4 | 84.1 | 57.2 | 30.8 | 15.8 | 12.2 | 8.6 | 3.9 | 54.6 | |
| MAPI | 2 | M | 64 | III | + | 30 | GST, MTX, NSAID | 2.7 | 85.7 | 63.5 | 26.4 | 16.8 | 14.3 | 13.2 | 4.8 | 129.6 |
| ROPI | F | 54 | III | + | 10 | CTX, GST, MTX, NSAID, S, SSZ | 2.7 | 77.7 | 54.9 | 22.2 | 24.5 | 18.5 | 10.0 | 6.0 | 162.0 | |
| PIPE | F | 69 | III | − | 13 | HCQ, MTX, NSAID, S | 2.5 | 82.1 | 58.7 | 29.1 | 23.3 | 16.7 | 13.4 | 6.1 | 152.5 | |
| GEGU | M | 62 | II | + | 9 | MTX, NSAID, S, SSZ | 1.8 | 74.2 | 46.3 | 32.0 | 38.4 | 26.3 | 22.6 | 7.0 | 126.0 | |
| GIVI | M | 54 | II | + | 2 | HCQ, MTX, NSAID, S, SSZ | 2.3 | 81.3 | 48.7 | 33.0 | 33.8 | 26.7 | 19.3 | 7.1 | 163.3 | |
| GIFE | M | 53 | II | + | 8 | MTX, NSAID, Q, SSZ | 2.0 | 88.0 | 40.4 | 54.9 | 36.1 | 33.8 | 32.6 | 7.2 | 144.0 | |
| INZA | F | 71 | III | + | 18 | DPA, MTX, NSAID, S | 1.5 | 80.4 | 57.6 | 32.9 | 35.0 | 22.4 | 19.0 | 8.3 | 124.5 | |
| LOME | M | 66 | II | + | 5 | NSAID, S, SSZ | 1.2 | 84.8 | 46.7 | 38.9 | 39.7 | 34.2 | 26.8 | 8.4 | 101.0 | |
| VIZA | F | 68 | II | + | 3 | HCQ, MTX, NSAID, S, SSZ | 1.4 | 84.6 | 31.5 | 46.5 | 47.8 | 45.9 | 36.1 | 8.6 | 120.0 | |
| MAGHI | F | 37 | I | + | 7 | HCQ, GST, NSAID | 1.8 | 57.8 | 41.4 | 20.0 | 35.5 | 18.0 | 8.4 | 10.1 | 181.8 | |
| Controls | M/F | 38.8 ± 5.5 | — | — | — | — | 2.0 ± 0.4 | 75.4 ± 8.3 | 50.4 ± 7.3 | 29.3 ± 6.7 | 16.5 ± 7.1 | 8.0 ± 4.6 | 10.4 ± 4.1 | 1.5 ± 1.2 | 30.1 ± 23.5 | |
| Patients . | Group . | Sex . | Age (yrs) . | ARA Class . | RF . | Duration (yrs) . | Therapy . | Lymphocytes (×103) . | CD3+ (%) . | CD4+ (%) . | CD8+ (%) . | CD57+ (%) . | CD3+CD57+ (%) . | CD8+CD57+ (%) . | CD4+CD57+ . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | . | . | . | . | . | . | . | . | . | % . | μL . |
| MAAP | 1 | F | 61 | I | − | 20 | DPA, NSAID, S | 1.4 | 48.5 | 31.2 | 22.7 | 27.4 | 2.9 | 8.7 | 0.3 | 4.2 |
| ROBR | F | 41 | I | + | 12 | CSA, MTX, S | 1.4 | 83.0 | 65.5 | 18.5 | 9.1 | 6.7 | 5.3 | 0.5 | 7.0 | |
| GRMU | F | 31 | II | + | 11 | HCQ, NSAID, S, SSZ | 2.3 | 71.1 | 31.1 | 41.0 | 18.8 | 13.0 | 11.6 | 0.6 | 13.8 | |
| ROGR | F | 48 | II | + | 7 | CSA, MTX, S, NSAID | 2.8 | 74.5 | 53.9 | 22.8 | 11.1 | 5.3 | 6.3 | 0.6 | 16.8 | |
| TEAG | F | 64 | II | − | 14 | HCQ, NSAID, S | 1.6 | 67.5 | 46.8 | 21.2 | 18.8 | 11.9 | 7.7 | 0.7 | 11.2 | |
| OSGA | M | 40 | III | − | 11 | CSA, GST, MTX, NSAID, S | 2.2 | 88.1 | 55.4 | 33.6 | 7.5 | 2.6 | 3.0 | 0.7 | 15.4 | |
| GAAR | F | 63 | III | + | 5 | GST, MTX, NSAID, S | 1.4 | 87.7 | 70.7 | 19.8 | 3.1 | 1.4 | 1.4 | 0.7 | 9.8 | |
| BRCA | M | 39 | III | + | 1 | HCQ, MTX, NSAID, S, SSZ | 1.4 | 72.3 | 45.7 | 36.3 | 8.9 | 7.3 | 7.9 | 1.0 | 14.0 | |
| DAFR | M | 59 | II | − | 13 | GST, NSAID, S | 2.7 | 68.0 | 60.2 | 8.4 | 7.6 | 4.3 | 5.2 | 2.1 | 56.7 | |
| ANAP | M | 48 | II | + | 12 | AF, NSAID | 2.4 | 55.8 | 41.0 | 27.4 | 30.8 | 12.4 | 16.2 | 2.2 | 52.8 | |
| GESA | F | 71 | IV | + | 16 | NSAID, S | 1.4 | 49.7 | 29.8 | 51.3 | 45.1 | 18.2 | 31.1 | 2.2 | 30.8 | |
| CABO | F | 53 | II | − | 21 | NSAID, S | 1.6 | 48.0 | 32.5 | 37.4 | 38.5 | 9.5 | 20.1 | 2.5 | 40.0 | |
| ROPE | F | 56 | III | − | 15 | NSAID, S | 1.1 | 82.5 | 53.1 | 26.8 | 14.0 | 10.2 | 8.6 | 3.0 | 33.0 | |
| PIZI | M | 56 | II | + | 12 | HCQ, MTX, NSAID, S, SSZ | 0.6 | 78.0 | 54.0 | 23.7 | 22.4 | 18.4 | 12.9 | 3.3 | 19.8 | |
| CAZI | F | 52 | III | + | 12 | MTX, NSAID, S, SSZ | 1.4 | 84.1 | 57.2 | 30.8 | 15.8 | 12.2 | 8.6 | 3.9 | 54.6 | |
| MAPI | 2 | M | 64 | III | + | 30 | GST, MTX, NSAID | 2.7 | 85.7 | 63.5 | 26.4 | 16.8 | 14.3 | 13.2 | 4.8 | 129.6 |
| ROPI | F | 54 | III | + | 10 | CTX, GST, MTX, NSAID, S, SSZ | 2.7 | 77.7 | 54.9 | 22.2 | 24.5 | 18.5 | 10.0 | 6.0 | 162.0 | |
| PIPE | F | 69 | III | − | 13 | HCQ, MTX, NSAID, S | 2.5 | 82.1 | 58.7 | 29.1 | 23.3 | 16.7 | 13.4 | 6.1 | 152.5 | |
| GEGU | M | 62 | II | + | 9 | MTX, NSAID, S, SSZ | 1.8 | 74.2 | 46.3 | 32.0 | 38.4 | 26.3 | 22.6 | 7.0 | 126.0 | |
| GIVI | M | 54 | II | + | 2 | HCQ, MTX, NSAID, S, SSZ | 2.3 | 81.3 | 48.7 | 33.0 | 33.8 | 26.7 | 19.3 | 7.1 | 163.3 | |
| GIFE | M | 53 | II | + | 8 | MTX, NSAID, Q, SSZ | 2.0 | 88.0 | 40.4 | 54.9 | 36.1 | 33.8 | 32.6 | 7.2 | 144.0 | |
| INZA | F | 71 | III | + | 18 | DPA, MTX, NSAID, S | 1.5 | 80.4 | 57.6 | 32.9 | 35.0 | 22.4 | 19.0 | 8.3 | 124.5 | |
| LOME | M | 66 | II | + | 5 | NSAID, S, SSZ | 1.2 | 84.8 | 46.7 | 38.9 | 39.7 | 34.2 | 26.8 | 8.4 | 101.0 | |
| VIZA | F | 68 | II | + | 3 | HCQ, MTX, NSAID, S, SSZ | 1.4 | 84.6 | 31.5 | 46.5 | 47.8 | 45.9 | 36.1 | 8.6 | 120.0 | |
| MAGHI | F | 37 | I | + | 7 | HCQ, GST, NSAID | 1.8 | 57.8 | 41.4 | 20.0 | 35.5 | 18.0 | 8.4 | 10.1 | 181.8 | |
| Controls | M/F | 38.8 ± 5.5 | — | — | — | — | 2.0 ± 0.4 | 75.4 ± 8.3 | 50.4 ± 7.3 | 29.3 ± 6.7 | 16.5 ± 7.1 | 8.0 ± 4.6 | 10.4 ± 4.1 | 1.5 ± 1.2 | 30.1 ± 23.5 | |
Abbreviations: RF, rheumatoid factor; AF, auranofin; CTX, cyclophosphamide; CSA, cyclosporin A; DPA, D-penicillamine; GST, gold sodium thiomalate; HCQ, hydroxychloroquine; NSAID, non-steroid antiinflammatory drugs; MTX, methotrexate; S, steroids; SSZ, sulfasalazine.